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Introduction: Overall, intra-arterial treatment (IAT)
proved to be beneficial in patients with acute ischaemic
stroke due to a proximal occlusion in the anterior
circulation. However, heterogeneity in treatment benefit
may be relevant for personalised clinical decision-
making. Our aim is to improve selection of patients for
IAT by predicting individual treatment benefit or harm.
Methods and analysis: We will use data collected in
the Multicenter Randomized Clinical Trial of
Endovascular Treatment for Acute Ischemic Stroke in
the Netherlands (MR CLEAN) trial to analyse the effect
of baseline characteristics on outcome and treatment
effect. A multivariable proportional odds model with
interaction terms will be developed to predict the
outcome for each individual patient, both with and
without IAT. Model performance will be expressed as
discrimination and calibration, after bootstrap
resampling and shrinkage of regression coefficients, to
correct for optimism. External validation will be
conducted on data of patients in the Interventional
Management of Stroke III trial (IMS III). Primary
outcome will be the modified Rankin Scale (mRS) at
90 days after stroke.
Ethics and dissemination: The proposed study will
provide an internationally applicable clinical decision
aid for IAT. Findings will be disseminated widely
through peer-reviewed publications, conference
presentations and in an online web application tool.
Formal ethical approval was not required as primary
data were already collected.
Trial registration numbers: ISRCTN10888758;
Post-results and NCT00359424; Post-resultsc.
INTRODUCTION
In 2015, ﬁve consecutive randomised
controlled trials (RCTs) showed that
intra-arterial treatment (IAT) improves func-
tional outcome in patients with a proximal
occlusion in the anterior circulation.1–6 This
was a major breakthrough in the ﬁeld, and
IAT is now implemented in updated guide-
lines on acute ischaemic stroke (AIS)
management.7
Ideally, IAT will be targeted at patients who
are expected to have optimal beneﬁt: perso-
nalised treatment. In this study protocol, we
present seven steps for development and val-
idation of a clinical decision aid to predict
which individual patients with AIS will
beneﬁt most from IAT.8 9
METHODS AND ANALYSIS
Step 1: problem definition and data inspection
Problem definition
RCTs provide estimates of treatment effects
for average patients. However, it is important
to take potential heterogeneity of treatment
effects into account. Clinically relevant differ-
ences in the absolute effect of a treatment
can be caused by (1) differences in the
Strengths and limitations of this study
▪ Multiple characteristics will be evaluated simul-
taneously to show clinically relevant heterogen-
eity in treatment benefit between patients.
▪ Multivariable prediction modelling substantially
increases statistical power compared with other
approaches and is more robust, especially in
small data sets.
▪ We will use a relatively small cohort for the
development of a prediction model.
▪ Using a proportional odds model requires the
assumption that the ORs are the same for each
cut-off of the modified Rankin Scale.
Mulder MJHL, et al. BMJ Open 2017;7:e013699. doi:10.1136/bmjopen-2016-013699 1
Open Access Protocol
group.bmj.com on April 28, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
relative treatment effect (predictive effects) and (2)
differences in baseline risk on the outcome of interest
(prognostic effects).10 11 For example, in the Multicenter
Randomized Clinical Trial of Endovascular Treatment
for Acute Ischemic Stroke in the Netherlands (MR
CLEAN) trial, there is no predictive effect of age; the
relative treatment effect is constant across age sub-
groups.1 This is demonstrated by a non-signiﬁcant test
for interaction between age and treatment (ﬁgure 1A).
However, variation in baseline risk on favourable out-
come according to age results in a larger absolute treat-
ment beneﬁt in younger patients (ﬁgure 1B).
Conventional subgroup analyses are focused mainly
on predictive effects and assess the effect of only one
variable at a time. If predictive and prognostic effects of
multiple characteristics are evaluated simultaneously in
multivariable prediction modelling, it is likely that larger
heterogeneity in treatment beneﬁt between individual
patients will be found. Our aim is to improve selection
of patients for IAT by predicting treatment beneﬁt or
harm for individual patients with stroke.
Development data
We will use data of the MR CLEAN trial (n=500), which
was a phase 3 multicentre clinical trial with randomised
treatment group assignment, open-label treatment and
blinded end point evaluation. IAT plus usual care
(which could include intravenous administration of alte-
plase) was compared with usual care alone. IAT con-
sisted of arterial catheterisation with a microcatheter to
the level of occlusion and delivery of a thrombolytic
agent, mechanical thrombectomy or both.1
Severity of stroke was assessed at baseline with the
National Institutes of Health Stroke Scale (NIHSS; range
0–42). Baseline CT was evaluated with the Alberta Stroke
Program Early CT Score (ASPECTS; range 0–10).
Baseline imaging (CT angiography) was used to deter-
mine the location of occlusion and to grade the quality
of collateral ﬂow to the ischaemic area with a four-point
scale. Detailed information about the MR CLEAN trial
can be found in the study protocol and the publication
of the main results.1 12
End points of interest
The primary outcome will be the modiﬁed Rankin Scale
(mRS), a seven-point scale ranging from 0 (no symp-
toms) to 6 (death) at 90 days after stroke.13 We will
provide estimates of treatment beneﬁt as the absolute
increase in probability on functional independence
(deﬁned as mRS 0–2) and survival (deﬁned as mRS 0–5).
Step 2: coding of variables
As variables, we will use patient characteristics that are
expected to predict outcome, or that are expected to
interact with treatment, based on expert opinion and
the recent literature (table 1). Non-linearity of continu-
ous variables will be tested by comparing the two log
likelihood of models with linear and restricted cubic
spline functions.14
Timing of treatment is an essential predictor of
outcome. Since time to randomisation was not a reliable
indicator for time to treatment in the MR CLEAN trial
and will not be applicable in clinical practice, we will use
time from stroke onset to groin puncture. Since time to
groin puncture is not observable in the control group,
we will explore imputation approaches based on the cor-
relation with time to randomisation. All other baseline
variable values are more than 98% complete in the MR
CLEAN data, so we choose simple imputation by the
mean for continuous variables and simple imputation by
the mode for categorical variables.
Steps 3 and 4: model specification and estimation
We will test the effect of variables on functional outcome
and treatment effect with proportional odds regression
modelling. All variables from table 1 will be tested for
effect on outcome and interaction with treatment effect.
Prognostic variables (main effects) and predictive vari-
ables (interaction effects) with a p value of 0.15 in uni-
variable and multivariable analyses will be included in
our ﬁnal model. A p value of 0.15 was chosen to make
the predictor selection less data driven and prevent over-
ﬁtting.14 31 We will perform shrinkage of all regression
coefﬁcients with ridge regression to prevent overﬁtting
of the model.14 Predicted probabilities for each of the
Figure 1 Relative risk (A) and absolute risk difference (B) for
good functional outcome (mRS 0–2) in MR CLEAN sort by
age. MR CLEAN, Multicenter Randomized Clinical Trial of
Endovascular Treatment for Acute Ischemic Stroke in the
Netherlands; mRS, modified Rankin Scale.
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mRS categories, with and without treatment, will be
derived from the ordinal model. All statistical analyses
will be performed within the computing environment R
V.3.2.2 (The R Foundation)
Step 5: model performance
Model performance will be expressed in discrimination
and calibration. Discrimination will be quantiﬁed with
the c-statistic. The c-statistic is similar to the area under
the curve for binary outcomes and estimates the prob-
ability that out of two randomly chosen patients, the
patient with the higher predicted probability of a good
outcome will indeed have a better outcome. Calibration
refers to the agreement between predicted and observed
risks and will be assessed graphically with validation
plots, and expressed as calibration slope and an inter-
cept. The calibration slope describes the relative overall
effect of the variables in the validation sample, and is
ideally equal to 1. The intercept indicates whether pre-
dictions are systematically too high or too low, and
should ideally be 0.32 We will calculate a general c-
statistic to express the performance of our ordinal
model and additional calibration plots with speciﬁc c-
statistics for the predictions of favourable functional
outcome (mRS 0–2) and survival (mRS 0–5).
Step 6: model validity
The c-statistic will be internally validated with a bootstrap
procedure (500 samples with replacement) to estimate
the degree of optimism in parameter estimates.8 After
penalisation of the regression coefﬁcients, we will exter-
nally validate the model on data of patients in the
Interventional Management of Stroke III trial (IMS III)
with an occlusion in the anterior circulation on non-
invasive vessel imaging.33 Coefﬁcients of the ﬁnal model
will be ﬁtted on the combined development and valid-
ation data sets.
After validation, we will assess whether the model can
be used to discriminate between patients with low and
high expected beneﬁt by making individual predictions
of outcome for all patients included in the development
and validation data.
Step 7: model presentation
The ﬁnal model will be digitally available for use in clin-
ical practice, both for mobile devices and as a web appli-
cation. It will provide predictions of all mRS categories
for each individual patient, both with and without IAT.
ETHICS AND DISSEMINATION
Findings will be disseminated widely through peer-
reviewed publications, conference presentations and in
an online web application tool. Formal ethical approval
was not required for this study as primary data were
already collected.
DISCUSSION
Compared with the current subgroup analyses on the
effect of IAT, our modelling approach has multiple
advantages. First, it accounts for the fact that patients
have multiple characteristics that simultaneously affect
the likelihood of treatment beneﬁt.34 Thus, our model
will show more clinically relevant heterogeneity in treat-
ment beneﬁt between patients. Second, a multivariable
prediction model substantially increases statistical power
Table 1 Patient characteristics that are expected to predict outcome (prognostic), or that are expected to interact with
treatment (predictive)
Per cent of data complete
in MR CLEAN Prognostic Predictive
Clinical
Age6 15 100% x
Baseline NIHSS16 17 100% x
History of diabetes mellitus18 100% x
History of previous stroke19 100% x
History of atrial fibrillation20 100% x
Prestroke mRS score19 100% x
Systolic blood pressure21 100% x
IV treatment with alteplase22–24 100% x
Time from onset stroke to groin puncture25 26 100%* x x
Radiological
ASPECTS6 27 99.2% x
Location of intracranial occlusion on non-invasive vessel imaging28 29 99.8% x
Collateral score on CTA29 30 98.4% x x
*Of patients undergoing intra-arterial treatment.
ASPECTS, Alberta Stroke Program Early CT score; CTA, CT angiography; IV, intravenous; NIHSS, National Institutes of Health Stroke Scale;
MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; mRS, modified
Rankin Scale.
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to identify heterogeneity in treatment effects compared
with other approaches.35 These include neural network
and decision trees. We use regression modelling since it
is considered more robust, especially in relatively small
data sets.36 37
There are some differences between patients included
in the MR CLEAN trial and the IMS III trial that may
inﬂuence the external validity of our model. IMS III
had different inclusion criteria, used older devices and
older treatment paradigms than MR CLEAN. In order
to overcome these limitations, we will use only those
patients in IMS III with an occlusion in the intracranial
anterior circulation on non-invasive vessel imaging.
We will compare the baseline characteristics of the
derivation and validation cohort and describe relevant
differences that might lead to an underestimation or
overestimation of the model performance. Interestingly,
a substantial treatment effect in the IMS III patients with
proven intracranial large vessel occlusion has been
reported.38
Furthermore, even though the MR CLEAN trial has
included most patients of the recent RCTs, the cohort
remains relatively small for the development of a predic-
tion model, especially for the selection of the main
effect and interaction effects. We will reduce regression
coefﬁcients to prevent overﬁtting and also perform
external validation. In the future, we will further validate
and update our model in the pooled individual patient
data of the Highly Effective Reperfusion evaluated in
Multiple Endovascular Stroke Trials (HERMES) collabor-
ation, harbouring data of all patients from recent rando-
mised trials regarding IAT (over 1700 patients in total).
Moreover, we aim to investigate the validity of our model
predicting outcome after treatment in clinical practice.
Our model will therefore be tested by applying it to
recently treated patients in all Dutch neurovascular
centres participating in the MR CLEAN Registry
(mrclean-trial.org).
We will use a proportional odds model to analyse the
full mRS score as outcome. Formally, this model requires
the assumption that the ORs are the same for each
cut-off of the mRS. However, previous studies have
shown that even if the proportionality assumption is vio-
lated, proportional odds analysis is still more efﬁcient
than dichotomisation.39 In addition, all recent RCTs on
the effect of IAT used the full mRS and analysed their
results with proportional odds regression.
CONCLUSION
The proposed study will provide an internationally
applicable clinical decision aid for the selection of
patients for IAT. We consider this study an important
next step towards personalised treatment of patients
with AIS.
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